Abstract:
Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are commonly referred to as “atypical parkinsonian syndromes” or “frontotemporal dementias.” Clinically, they are characterized by an akinetic-rigid syndrome and cognitive impairment combined with a variety of so-called “plus features.” On pathological grounds, their hallmarks are certain neurodegenerative lesion patterns coupled with tau protein-positive intracellular protein aggregates in both neuronal and glial cells bodies or their processes. The pathogenesis of these disorders is not fully elucidated yet. Both genetic and environmental factors may be contributory. Here we review briefly the clinical presentation, comment on the neuropathology, and discuss in more detail the current state of pathogenetic concepts of these disorders with a special focus on recent genetic findings.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AD:
-
Alzheimer's disease
- CBD:
-
corticobasal degeneration
- FTDP-17:
-
frontotemporal dementia with parkinsonism linked to chromosome 17
- 3R-tau:
-
3 repeat tau
- 4R-tau:
-
4 repeat tau
- PD:
-
Parkinson's disease
- PiD:
-
Pick's disease
- PSP:
-
progressive supranuclear palsy
- TIQs:
-
tetrahydroisoquinolines
References
Arima K, Nakamura M, Sunohara N, Ogawa M, Anno M, et al. 1997. Ultrastructural characterization of the tau-immunoreactive tubules in the oligodendroglial perikarya and their inner loop processes in progressive supranuclear palsy. Acta Neuropathol (Berl) 93(6): 558–566.
Armstrong RA, Cairns NJ, Lantos PL. 2000. A quantitative study of the pathological lesions in the neocortex and hippocampus of twelve patients with corticobasal degeneration. Exp Neurol 163(2): 348–356.
Armstrong R, Lantos PL, Cairns NJ. 2005. Overlap between neurodegenerative disorders. Neuropathol 25: 111–124.
Baker M, Litvan I, Houlden H, Adamson J, Dickson D, et al. 1999. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8: 711–715.
Bergeron C, Pollanen MS, Weyer L, Lang AE. 1997. Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. J Neuropathol Exp Neurol 56(6): 726–734.
Boeve BF, Maraganore DM, Parisi JE, Ahlskog JE, Graff-Radford N, et al. 1999. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 53(4): 795–800.
Boeve BF, Lang AE, Litvan I. 2003. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 54 (Suppl. 5): S15–S19.
Bower J, Maraganore D, McDonnell S, Rocca W. 1997. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49: 1284–1288.
Buee L, Delacourte A. 1999. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol 9: 681–693.
Bugiani O, Murrell JR, Giaccone G, Hasegawa M, Ghigo G, et al. 1999. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol 58: 667–677.
Bugiani O, Mancardi GL, Brusa A, Ederli A. 1979. The fine structure of subcortical neurofibrillary tangles in progressive supranuclear palsy. Acta Neuropathol 45: 147–152.
Burn DJ, Lees AJ. 2002. Progressive supranuclear palsy: Where are we now? Lancet Neurol 1(6): 359–369.
Caparros-Lefebvre D, Elbaz A. 1999. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: A case-control study. Caribbean Parkinsonism Study Group. Lancet 354(9175): 281–286.
Caparros-Lefebvre D, Sergeant N, Lees A, Camuzat A, Daniel S, et al. 2002. Guadeloupean parkinsonism: A cluster of progressive supranuclear palsy-like tauopathy. Brain 125(Pt 4): 801–811.
Case Records of the Massachusetts General Hospital 1993. Case 38–1985: Case of corticonigral degeneration with neuronal achromasia. N Eng J Med 329: 1560–1567.
Castellani R, Smith MA, Richey PL, Kalaria R, Gambetti P, et al. 1995. Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res 696(1–2): 268–271.
Conrad C, Andreadis A, Trojanowski JQ, Dickson DW, Kang D, et al. 1997. Genetic evidence for the involvement of τ in progressive supranuclear palsy. Ann Neurol 41: 277–281.
Cordato NJ, Halliday GM, Harding AJ, Hely MA, Morris JG. 2000. Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann Neurol 47(6): 718–728.
Couchie D, Mavilia C, Georgieff IS, Liem RK, Shelanski ML, et al. 1992. Primary structure of high molecular weight tau present in the peripheral nervous system. Proc Natl Acad Sci USA 89(10): 4378–4381.
Cummings JL, Litvan I. 2000. Neuropsychiatric aspects of corticobasal degeneration. “Corticobasal Degeneration”. Advances in Neurology, Vol. 82. Litvan I, Goetz CG, Lang AE, editors. Philadelphia: Lippincott Williams & Wilkins; pp. 147–152.
Cruz-Sanchez FF, Rossi ML, Cardozo A, Picardo A, Tolosa E. 1992. Immunohistological study of grumose degeneration of the dentate nucleus in progressive supranuclear palsy. J Neurol Sci 110(1–2): 228–231.
Davis PH, Golbe LI, Duvoisin RC, Schoenberg BS. 1988. Risk factors for progressive supranuclear palsy. Neurology 38(10): 1546–1552.
Delisle MB, Murrell JR, Richardson R, Trofatter JA, Rascol O, et al. 1999. A mutation at codon 279 (N279K) in exon 10 of the tau gene causes a tauopathy with dementia and progressive supranuclear palsy. Acta Neuropathol 98: 62–77.
de Silva R, Hope A, Pittman A, Weale ME, Morris HR, et al. 2003. Strong association of the Saitohin gene Q7 variant with progressive supranuclear palsy. Neurology 61: 407–409.
de Yebenese JG, Sarasa JL, Daniel SE, Lees AL. 1995. Familial progressive supranuclear palsy: Description of a pedigree and review of the literature. Brain 118: 1095–1103.
Dickson DW. 1999. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 246: II6–15.
Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, et al. 2002. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61(11): 935–946.
Dickson DW, Liu WK, Ksiezak-Reding H, Yen SH. 2000. Neuropathologic and molecular considerations. Adv Neurol 82: 9–27.
di Maria E, Tabaton M, Vigo T, Abbruzzese G, Bellone E, et al. 2000. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol 47(3): 374-377.
Drache B, Diehl GE, Beyreuther K, Perlmutter LS, Konig G. 1997. Bcl-xl-specific antibody labels activated microglia associated with Alzheimer's disease and other pathological states. J Neurosci Res 47(1): 98–108.
Feany MB, Dickson DW. 1995. Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 146: 1388–1396.
Feany MB, Dickson DW. 1996. Neurodegenerative disorders with extensive tau pathology: A comparative study and review. Ann Neurol 40(2): 139–148.
Feany MB, Mattiace LA, Dickson DW. 1996. Neuropathologic overlap of progressive supranuclear palsy, Pick's disease and corticobasal degeneration. J Neuropathol Exp Neurol 55: 53–67.
Flament S, Delacourte A, Verny M, Hauw JJ, Javoy-Agid F. 1991. Abnormal tau proteins in progressive supranuclear palsy: Similarities and differences with the neurofibrillary degeneration of the Alzheimer type. Acta Neuropathol 81: 591–596.
Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, et al. 2006. Frontotemporal dementia: Clinicopathological correlations. Ann Neurol 59(6): 952–962.
Friedrich MJ. 1999. Pesticide study aids Parkinson research. JAMA 282: 2200.
Georgieff IS, Liem RK, Mellado W, Nunez J, Shelanski ML. 1991. High molecular weight tau: Preferential localization in the peripheral nervous system. J Cell Sci 100(1): 55–60.
Gerhard A, Banati RB, Cagnin A, Brooks DJ. 2001. In vivo imaging of activated microglia with [11C]PK11195 positron emission tomography (PET) in idiopathic and atypical Parkinson's disease. Neurology 56: 270.
Gerhard A, Watts J, Trender-Gerhard I, Turkheimer F, Banati RB, et al. 2004. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord 19(10): 1221–1226.
Gibb WRG, Luthert PJ, Marsden CD. 1989. Corticobasal degeneration. Brain 112: 1171–1192.
Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, et al. (1996) Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulfated glycosaminoglycans. Nature 282: 550–553.
Goedert M, Spillantini MG, Crowther RA. 1992. Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system. Proc Natl Acad Sci USA 89(5): 1983–1987.
Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. 1989. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles in Alzheimer's disease. Neuron 3: 519–526.
Golbe LI. 2000. Progressive supranuclear palsy in the molecular age. Lancet 356(9233): 870–871.
Golbe LI, Rubin RS, Cody RP, Belsh JM, Duvoisin RC, et al. 1996. Follow-up study of risk factors in progressive supranuclear palsy. Neurology 47(1): 148–154.
Gong CX, Liu F, Grundke-Iqbal I, Iqbal K. 2005. Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 112(6): 813–838.
Graham NL, Bak TH, Hodges JR. 2003. Corticobasal degeneration as a cognitive disorder. Mov Disord 18(11): 1224–1232.
Greenberg SG, Davis P. 1990. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA 87(15): 5827–5831.
Grimes DA, Lang AE, Bergeron CB. 1999. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 53(9): 1969–1974.
Halliday GM, Hardman CD, Cordato NJ, Hely MA, Morris JG. 2000. A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy. Brain 123 (Pt 4): 724–732.
Hardy J, Pittman A, Myers A, Gwinn-Hardy K, Fung HC, 2005. Evidence suggesting that Homo neanderthalensis contributed the H2 MAPT haplotype to Homo sapiens. 32(4): 582–585.
Hartzler AW, Zhu X, Siedlak SL, Castellani RJ, Avila J, et al. 2002. The p38 pathway is activated in Pick disease and progressive supranuclear palsy: A mechanistic link between mitogenic pathways, oxidative stress, and tau. Neurobiol Aging 23(5): 855–859.
Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, et al. 1994. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 44(11): 2015–2019.
Higuchi Y, Iwaki T, Tateishi J. 1995. Neurodegeneration in the limbic and paralimbic system in progressive supranuclear palsy. Neuropathol Appl Neurobiol 21: 246–254.
Hof PR, Nimchinsky EA, Buee-Scherrer V, Buee L, Nasrallah J, et al. 1994. Amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: Quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders. Acta Neuropathol 88(5): 397–404.
Horiguchi T, Uryu K, Giasson BI, Ischiropoulos H, Light Foot R, et al. 2003. Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol 163(3): 1021–1031.
Houlden H, Baker M, Morris HR, Mac Donald N, Pickering-Brown S, et al. 2001. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56: 1702–1706.
Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. 2002. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125(Pt 4): 861–870.
Hutton M. 2000. “Missing” tau mutation identified. Ann Neurol 47: 417–418.
Ikeda K, Akiyama H, Arai T, Tsuchiya K. 2002. Pick-body-like inclusions in corticobasal degeneration differ from Pick bodies in Pick's disease. Acta Neuropathol (Berl) 103: 115–118.
Ikeda K, Akiyama H, Haga C, Kondo H, Arima K, et al. 1994. Argyrophilic thread-like structure in corticobasal degeneration and supranuclear palsy. Neurosci Lett 174: 157–159.
Ishizawa K, Dickson DW. 2001. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol 60: 647–657.
Jellinger KA, Blancher C. 1992. Neuropathology. Progressive Supranuclear Palsy: Clinical and Research Approaches. Litvan I, Agid Y, editors. Oxford: Oxford University Press; pp. 44–88.
Jiang Z, Cote J, Kwon JM, Goate AM, Wu JY. 2000. Aberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia frontotemporal dementia with Parkinsonism linked to chromosome 17. Mol Cell Biol 20: 4036–4048.
Jiang Y, Tang H, Havlioglu N, Zhang X, Stamm S, et al. 2003. Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2β. J Biol Chem 278: 18997–19007.
Josephs KA, Dickson DW. 2003. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord 18(9): 1018–1026.
Kawai H, Makino Y, Hirobe M, Ohta S. 1998. Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivative: Uptake by dopamine transporter and activity to induce parkinsonism. J Neurochem 70: 745–751.
Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. 2005. The evolution and pathology of frontotemporal dementia. 128(Pt 9): 1996-2005.
Kikuchi K, Nagatsu Y, Makino Y, Mashino T, Ohta S, et al. 1991. Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds 1,2,3,4-tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline. Drug Metab Dispos 19(1): 257–262.
Komori T. 1999. Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol 9: 663–679.
Komori T, Arai N, Oda M, Nakayama H, Mori H, et al. 1998. Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol (Berl) 96(4): 401–408.
Kondo S, Yamamoto N, Murakami T, Okumura M, Mayeda A, et al. 2000. Tra2β, SF2/ASF and SRp30c modulate the function of an exonic splicing enhancer in exon 10 of tau pre-mRNA. Genes Cells 9: 121–130.
Kotake Y, Tasaki Y, Yea. Makino 1995. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: A novel endogenous amine in mouse brain and parkinsonian CSF. J Neurochem 65: 2633–2638.
Kotake T, Yoshida M, Ogawa M, Tasaki Y, Hirobe M, et al. 1996. Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate. Neurosci Lett 217: 69–71.
Ksiezak-Reding H, Morgan K, Mattiace LA, Davies P, Liu W-K, et al. 1994. Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration. Am J Pathol 145: 1496–1508.
Kumar R, Bergeron C, Lang AE. 2002. Corticobasal degeneration. Parkinson's Disease and Movement Disorders, Jankovic J, Tolosa E, editors. 4th edition. Philadelphia: Lippincott Williams & Wilkins; pp. 185–198.
Lang AE. 2003. Corticobasal degeneration: Selected developments. Mov Disord 18(Suppl. 6): S51–S56.
Lang A, Riley D, Bergeron C. 1994. Cortical-basal degeneration. Neurodegenerative Diseases. Calne D, editor. Philadelphia: Saunders; pp. 877–894.
Lannuzel A, Michel PP, Abaul MJ, Caparros-Lefebvre D, Ruberg M. 2000. Neurotoxic effects of alkaloids from Annona muricata (soursop) on dopaminergic neurons: Potential role in etiology of atypical parkinsonism in French West Indies. Mov Disord 13(Suppl. 3): 28.
Lee V, Goedert M, Tojanowski JQ. 2001. Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121–1159.
Lippa CF, Flanders KC, Kim ES, Croul S. 1998. TGF-β receptors-I and -II immunoexpression in Alzheimer's disease: A comparison with aging and progressive supranuclear palsy. Neurobiol Aging 19(6): 527–533.
Litvan I. 2003. Update on epidemiological aspects of progressive supranuclear palsy. Mov Disord 18 (Suppl. 6): S43-S50.
Litvan I. 2005a. Progressive supranuclear palsy. Scientific Basis for Treatment of Parkinson's disease. Galvez-Jimenez N, editor. London, NewYork: Taylor & Francis; pp. 267–278.
Litvan I. 2005b. Progressive supranuclear palsy and corticobasal degeneration. Animal Models of Movement Disorders. LeDoux M, editor. Amsterdam: Elsevier; pp. 505–514.
Litvan I, Baker M, Hutton M. 2001. Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy. Neurology 57: 138–140.
Litvan I, Agid Y, Calne D, Campbell G, Dubois B, et al. 1996a. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology 47(1): 1–9.
Litvan I, Mangone CA, McKee A, Verny M, Parsa A, et al. 1996b. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: A clinicopathological study. J Neurol Neurosurg Psychiat 60: 615–620.
Mackenzie IRA, Hudson LP. 1995. Achromatic neurons in the cortex of progressive supranuclear palsy. Acta Neuropathol (Berl) 90: 615–619.
Mahapatra RK, Edwards MJ, Schott JM, Bhatia KP. 2004. Corticobasal degeneration. Lancet Neurol 3(12): 736–743.
Makino Y, Ohta S, Tachikawa O, Hirobe M. 1988. Presence of tetrahydroisoquinoline and 1-methyl-tetrahydro-isoquinoline in foods: Compounds related to Parkinson's disease. Life Sci 43: 373–378.
Makino Y, Ohta S, Tasaki Y, Tachikawa O, Kashiwasake M, et al. 1990. A novel and neurotoxic tetrahydroisoquinoline derivative in vivo: Formation of 1,3-dimethyl-1,2,3,4-tetrahydroisoquinoline, a condensation product of amphetamines, in brains of rats under chronic ethanol treatment. J Neurochem 55: 963–969.
Maraganore D, Ahlskog J, Petersen R. 1992. Progressive asymmetric rigidity with apraxia: A distinct clinical entity. Mov Disord 7(Suppl. 1): 80.
McCrank E. 1990. PSP risk factors. Neurology 40(10): 1637.
McCrank E, Rabheru K. 1989. Four cases of progressive supranuclear palsy in patients exposed to organic solvents. Can J Psychiatry 34(9): 934–936.
Miller ML, Johnson JVW. 1995. Transglutaminase cross-linking of the τ protein. J Neurochem 65: 1760–1770.
Morimatsu M, Negoro K. 2002. Provisional diagnostic criteria of corticobasal degeneration (CBD) and the survey of patients with CBD in Japan. Rinsho Shinkeigaku 42(11): 1150–1153.
Morris HR, Vaughan JR, Datta SR, Bandopadhyay R, Rohan De Silva HA, et al. 2000. Multiple system atrophy/progressive supranuclear palsy: α-Synuclein, synphilin, tau, and APOE. Neurology 55(12): 1918–1920.
Morris HR, Gibb G, Katzenschlager R, Wood NW, Hanger DP, et al. 2002. Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain 125: 969–975.
Morris HR, Osaki Y, Holton J, Lees AJ, Wood NW, et al. 2003. Tau exon 10+16 mutation FTDP-17 presenting clinically as sporadic young onset PSP. Neurology 61: 102–104.
Nicholl DJ, Bennett P, Hiller L, Bonifati V, Vanacore N, et al. 1999. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology 53(7): 1415–1421.
Niwa T, Takeda N, Sasaoka T, Kaneda T, et al. 1989a. Detection of tetrahydroisoquinoline, in parkinsonian brain as an endogenous amine by use of gas chromatography-mass spectrometry. J Chromatogr 491: 397–403.
Niwa T, Yoshizumi H, Aea. Tatematsu 1989b. Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods. J Chromatogr 493: 347–352.
Oyanagi K, Tsuchiya K, Yamazaki M, Ikeda K. 2001. Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: Specific pathological features. J Neuropathol Exp Neurol 60: 393–402.
Pastor P, Pastor E, Carnero C, Vela R, Garcia T, et al. 2001. Familial atypical progressive supranuclear palsy associated with homozygosity for del N296 mutation in the tau gene. Ann Neurol 49: 263–267.
Perez M, Valpuesta JM, Medine M, Montejo de Garcini E, Avila J. 1996. Polymerization of tau into filaments in the presence of heparin: The minimal sequence requirement for tau-tau interactions. J Neurochem 67: 1183–1190.
Pezzoli G, Ricciardi S, Masotto C, Mariani CB, Carenzi A. 1990. n-Hexane induces parkinsonism in rodents. Brain Res 531(1–2): 355–357.
Pezzoli G, Barbieri S, Ferrante C, Zecchinelli A, Foa V. 1989. Parkinsonism due to n-Hexane exposure. Lancet 2(8667): 874.
Poewe W, Wenning GK. 2003. Atypical parkinsonism. Neurological Disorders: Course and Treatment. Brandt T, Caplan LR, Dichans J, Diener HC, Kennard C, editors. Amsterdam: Elsevier; pp. 1081–1098.
Poorkaj P, Muma NA, Zhukareva V, Cochran EJ, Shannon KM, et al. 2002. An R5L mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol 52: 511–516.
Powell HC, London GW, Lampert PW. 1974. Neurofibrillary tangles in progressive supranuclear palsy: Electron microscopic observations. J Neuropathol Exp Neurol 33: 98–106.
Rebeiz JJ, Kolodny EH, Richardson EP Jr. 1968. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 18(1): 20–33.
Riley DE, Lang AE, Lewis A, Resch L, Ashby P, et al. 1990. Cortical-basal ganglionic degeneration. Neurology 40(8): 1203–1212.
Riley DE, Lang AE. 2000. Clinical diagnostic criteria. Adv Neurol 82: 29–34.
Riley DE, Moro-de-Casillas ML. 2005. Cortico-basal degeneration. Scientific Basis for the Treatment of Parkinson's Disease. Galvez-Jimenez N, editor. London, NewYork: Taylor & Francis; pp. 279–289.
Rinne JO, Lee MS, Thompson PD, Marsden CD. 1994. Corticobasal degeneration. A clinical study of 36 cases. Brain 117 (Pt 5): 1183–1196.
Rojo A, Pernaute RS, Fontan A, Ruiz PG, Honnorat J, et al. 1999. Clinical genetics of familial progressive supranuclear palsy. Brain 122: 1233–1245.
Ros R, Garre PG, Hirano M, Tai YF, Ampuero I, et al. 2005. Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1. Ann Neurol 57: 634–641.
Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, et al. 1998. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 153(4): 1149–1155.
Schrag A, Ben Shlomo Y, Quinn NP. 1999. Prevalence of progressive supranuclear palsy and multiple system atrophy: A cross-sectional study. Lancet 354(9192): 1771–1775.
Schweitzer K, Decker E, Zhu L, Miller RE, Mirra SS, et al. 2006. Aberrantly regulated proteins in frontotemporal dementia. Biochem Biophys Res Commun 348(2): 465–472.
Smith TW, Lippa CF, de Girolami U. 1992. Immunocytochemical study of ballooned neurons in cortical degeneration with neuronal achromasia. Clin Neuropathol 11(1): 28–35.
Soto-Otero R, Mendez-Alvarez E, Sanchez-Sellero I, Cruz-Landeira A, Lopez-Rivadulla Lamas M. 2001. Reduction of rat brain levels of the endogenous dopaminergic proneurotoxins 1,2,3,4-tetrahydroisoquinoline and 1,2,3,4-tetrahydro-β-carboline by cigarette smoke. Neurosci Lett 298: 187–190.
Spillantini MG, Goedert M. 2001. Tau and Parkinson disease. JAMA 286: 2324–2326.
Spillantini MG, Yoshida H, Rizzini C, Lantos PL, Khan N, et al. 2000. A novel mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Ann Neurol 48: 939–943.
Stanford PM, Halliday GM, Brooks WS, Kwok JB, Store CE, et al. 2000. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: Expansion of the disease phenotype caused by tau gene mutations. Brain 123: 880–893.
Steele JC, Richardson JC, Olszewski J. 1964. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10: 333–359.
Stefansson H, Helgason A, Thorleifsson G, Steinthorsdottir V, Masson G, et al. 2005. A common inversion under selection in Europeans. Nat Genet 37(2): 129–137.
Swerdlow RH, Golbe LI, Parks JK, Cassarino DS, Binder DR, et al. 2000. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J Neurochem 75: 1681–1685.
Tasaki Y, Makino Y, Ohta S, Hirobe M. 1991. 1-Methyl-1,2,3,4-tetrahydroisoquioline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities. J Neurochem 57: 1940–1943.
Tawana K, Ramsden DB. 2001. Progressive supranuclear palsy. Mol Pathol 54(6): 427–434.
Tetrud JW, Langston JW, Irwin I, Snow B. 1994. Parkinsonism caused by petroleum waste ingestion. Neurology 44(6): 1051–1054.
Togo T, Dickson D. 2002. Ballooned neurons in PSP are usually due to concurrent argyrophilic grain disease. Acta Neuropathol (Berl) 104: 5356.
Toloso E, Valldeoriola F, Pastor P. 2002. Progressive supranuclear palsy. Parkinson's Disease and Movement Disorders. Jankovic J, Tolosa E, editors. 4th edition. Philadelphia:Lippincott Williams & Wilkins; pp. 152–169.
Tsuchiya K, Uchihara T, Oda T, Arima K, Ikeda K, et al. 1997. Basal ganglia lesions in corticobasal degeneration differ from those in Pick's disease and progressive supranuclear palsy: A topographic neuropathological study of six autopsy cases. Neuropathology 17: 208–216.
Uchihara T, Mitani K, Mori H, Kondo H, Yamada M, et al. 1994. Abnormal cytoskeletal pathology peculiar to corticobasal degeneration is different from that of Alzheimer's disease or progressive supranuclear palsy. Acta Neuropathol (Berl) 88(4): 379–383.
Uchihara T, Mizusawa H, Tsuchiya K, Kondo H, Oda T, et al. 1998. Discrepancy between tau immunoreactivity and argyrophilia by the Bodian method in neocortical neurons of corticobasal degeneration. Acta Neuropathol 96: 553–557.
Vanacore N, Bonifati V, Colosimo C, Fabbrini G, De Michele G, et al. 2001. Epidemiology of progressive supranuclear palsy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci 22(1): 101–103.
Vanacore N, Bonifati V, Fabbrini G, Colosimo C, Marconi R, et al. 2000. Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology 54(1): 114-119.
Varani L, Spillantini MG, Goedert M, Varani G. 2000. Structural basis for recognition of the RNA major groove in the tau exon 10 splicing regulatory element by aminoglycoside antibiotics. Nucleic Acids Res 28(3): 710–719.
Vermersch P, Robitaille Y, Berneir L, Wattez A, Gauvreau D, et al. 1994. Biochemical mapping of neurofibrillary degeneration in a case of progressive supranuclear palsy: Evidence for general cortical involvement. Acta Neuropathol 87: 572–577.
von Bergen M, Barghorn S, Muller SA, Pickhardt M, Biernat J, et al. 2006. The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. Biochemistry 45(20): 6446–6457.
Wakabayashi K, Takahashi H. 1996. Similarities and differences among progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Neuropathology 16: 262–268.
Wakabayashi K, Takahashi H. 2004. Pathological heterogeneity in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 24(1): 79–86.
Watts RL, Mirra SS, Young RR. 1989. Corticobasal ganglionic degeneration (CBDG) with neuronal achromasia: Clinical-pathological study of two cases. Neurology 39: 140.
Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, et al. 1998. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 64(2): 184–189.
Williams DR. 2006. Tauopathies: Classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern Med J 36(10): 652–660.
Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, et al. 2005. Characteristics of two distinct phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 128(6): 1247–1258.
Yagishita S, Itoh Y, Amano N, Nakano T, Saitoh A. 1979. Ultrastructure of neurofibrillary tangles in progressive supranuclear palsy. Acta Neuropathol 48: 27–30.
Yamada T, Moroo I, Koguchi Y, Asahina M, Hirayama K. 1994. Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear pals. Acta Neurol Scand 89: 42–46.
Yoshida M, Niwa T, Nagatsu T. 1990. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes. Neurosci Lett 119: 109–113.
Zemaitaitis MO, Lee JM, Troncoso JC, Muma NA. 2000. Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy. J Neuropathol Exp Neurol 59(11): 983–989.
Zemaitaitis MO, Kim SY, Halverson RA, Troncoso JC, Lee JM, et al. 2003. Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J Neuropathol Exp Neurol 62(2): 173–184.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this entry
Cite this entry
Geser, F., Scholz, S.W., Wenning, G.K. (2007). Progressive Supranuclear Palsy and Corticobasal Degeneration. In: Lajtha, A., Youdim, M.B.H., Riederer, P., Mandel, S.A., Battistin, L. (eds) Handbook of Neurochemistry and Molecular Neurobiology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-30377-2_8
Download citation
DOI: https://doi.org/10.1007/978-0-387-30377-2_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-30344-4
Online ISBN: 978-0-387-30377-2
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences